Juvenescence has closed its Series B-1 financing round, securing $76 million led by Abu Dhabi’s M42. The collaboration establishes an AI-enabled drug development hub leveraging clinical data, genomics, and AI-driven discovery. This partnership accelerates Juvenescence’s pipeline of therapeutics against age-related diseases, spanning cognition, cardio-metabolism, immunity, and cellular repair to extend healthy lifespan.

Key points

• Juvenescence raises $76 million in Series B-1 funding led by Abu Dhabi’s M42 to support its AI-driven longevity pipeline.
• Partnership establishes an AI-enabled drug development hub integrating M42’s genomics and clinical-data infrastructure with Juvenescence’s discovery platform.
• Therapeutic programs target cognition, cardiometabolic function, immune modulation, and cellular repair to address age-related disease hallmarks.

Why it matters: This strategic funding and partnership establish a scalable AI-driven platform to accelerate discovery of longevity therapeutics, potentially transforming age-related disease treatment.